Radio(chemo)therapy in locally advanced nonsmall cell lung cancer (Q26765355)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

title

Radio(chemo)therapy in locally advanced nonsmall cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Markus Glatzer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

Sara Ramella

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

Ursula Nestle

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

Paul Martin Putora

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

1 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

European Respiratory Review

9 March 2020

published in

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

issue

139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

65-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

Stereotactic body radiation therapy for inoperable early stage lung cancer

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non–small-cell lung cancer: Long-term results of a radiation dose escalation study

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Adding Ipsilateral V20 and V30 to Conventional Dosimetric Constraints Predicts Radiation Pneumonitis in Stage IIIA–B NSCLC Treated With Combined-Modality Therapy

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Radiation dose-volume effects in the heart

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Radiation dose-volume effects in the spinal cord.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Radiation dose-volume effects in the lung.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Are the results of RTOG 0617 mysterious?

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Long-term survival with surgery as part of a multimodality approach for N3 lung cancer.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 S

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-c

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1183/16000617.0053-2015

7 January 2021

10.1183/16000617.0053-2015

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929423 AND SRC:MED&resulttype=core&format=json